Clinical Utility of Serum Interleukin-8 and Interferon-Alpha in Thyroid Diseases

Table 4

Significance of IFN-α levels in patients with thyroid diseases as compared to healthy individuals.

Subjects	Mean ± S.E (IU/ml)	Median	Minimum	Maximum	P value
Healthy individuals	2.41 ± 0.18	2.26	0.50	4.00
Total patients	3.82 ± 0.50				.002
Goitre	3.40 ± 0.30	3.14	2.27	9.07	.001
Autoimmune disorders	2.97 ± 0.12	3.02	2.01	4.16	.009
Graves’ disease	2.91 ± 0.15				.028
Hashimoto disorder	3.14 ± 0.21				.054
Thyroid carcinoma	4.51 ± 1.06	3.21	2.14	36.67	<.001
Papillary carcinoma	5.10 ± 1.87				.003
Follicular carcinoma	3.48 ± 0.31				.007
Medullary carcinoma	4.72 ± 1.29				.006
Anaplastic carcinoma	3.10 ± 0.27				.087
Early stage (Stage I & II)	5.37 ± 2.24				.007
Advanced stage (Stage III & IV)	3.76 ± 0.36				<.001